ProPhase Labs shares surge 19.39% premarket after securing USPTO patent for esophageal adenocarcinoma risk assessment test.

ProPhase Labs Inc. (NASDAQ:PRPH) surged 19.39% in premarket trading, driven by recent positive developments including the full U.S. Patent and Trademark Office approval for its esophageal adenocarcinoma risk assessment test on August 12, 2025. This intellectual property milestone, coupled with a successful clinical study demonstrating the BE-Smart™ test’s efficacy in detecting esophageal cancer, reinforced investor confidence in the company’s diagnostic platform commercialization prospects. Additionally, the completion of a $3 million senior secured convertible notes financing in July 2025 and the appointment of a new fractional CFO in August provided further strategic and financial stability, aligning with the stock’s bullish momentum.